Scarica l'app Stockscreener
6.48
0.46%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$6.51
Aprire:
$6.5
Volume 24 ore:
3.81M
Relative Volume:
1.43
Capitalizzazione di mercato:
$2.00B
Reddito:
$493.67M
Utile/perdita netta:
$-104.69M
Rapporto P/E:
-19.06
EPS:
-0.34
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-13.60%
1M Prestazione:
-27.03%
6M Prestazione:
-38.29%
1 anno Prestazione:
-42.25%
Intervallo 1D:
$6.325
$6.78
Intervallo di 1 settimana:
$6.20
$7.54
Portata 52W:
$6.20
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.48 | 2.00B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Amicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week LowHere's What Happened - MarketBeat
Norges Bank Invests $29.03 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Price Down 6.3%Here's What Happened - MarketBeat
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In? - Insider Monkey
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
ExodusPoint Capital Management LP Trims Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Massachusetts Financial Services Co. MA Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Fabry Disease Treatment Market Opportunity and Forecast Report 2025-2034 Featuring Amicus Therapeutics, Avrobio, Freeline, Idorsia, ISU Abxis, JCR, Novartis, Pfizer, Protalix, Sanofi, Takeda, Viatris - Yahoo Home
Analysts Expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) To Breakeven Soon - Yahoo Finance
Old West Investment Management LLC Grows Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Vanguard Group Inc. Has $275.62 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
JPMorgan Chase & Co. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics stock hits 52-week low at $6.99 By Investing.com - Investing.com South Africa
Amicus Therapeutics stock hits 52-week low at $6.99 - Investing.com
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires? - Insider Monkey
Research Analysts Issue Forecasts for FOLD Q1 Earnings - MarketBeat
Trexquant Investment LP Acquires 486,827 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
AMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. - Bluefield Daily Telegraph
AMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces - GlobeNewswire
Zacks Research Analysts Increase Earnings Estimates for FOLD - MarketBeat
Pictet Asset Management Holding SA Sells 110,241 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
KLP Kapitalforvaltning AS Purchases New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 52-Week LowHere's What Happened - MarketBeat
Wellington Management Group LLP Buys 4,497,950 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75 - MarketBeat
Relative Strength Alert For Amicus Therapeutics - Nasdaq
Amicus Therapeutics stock hits 52-week low at $8.09 - Investing.com
Amicus Therapeutics stock hits 52-week low at $8.09 By Investing.com - Investing.com Australia
How To Trade (FOLD) - news.stocktradersdaily.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Fox Run Management L.L.C. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Trading Down 2.5%Time to Sell? - MarketBeat
Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment? - simplywall.st
Intech Investment Management LLC Has $1.18 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Treatment Market Size in 7MM is expected to grow at - openPR.com
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amicus Therapeutics Inc Azioni (FOLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Campbell Bradley L | President and CEO |
Feb 19 '25 |
Sale |
10.00 |
400 |
4,000 |
1,150,657 |
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):